Beam Therapeutics 更新了 Ristoglogene Autogetemcel (Risto-Cel) 在美国血液学会 (ASH) 年会上关于 Beacon 1/2 期临床试验的数据,强调了其在镰状细胞病 (SCD) 中的持久和差异化疗效。
Beam Therapeutics 更新了 Ristoglogene Autogetemcel (Risto-Cel) 在美国血液学会 (ASH) 年会上关于 Beacon 1/2 期临床试验的数据,强调了其在镰状细胞病 (SCD) 中的持久和差异化疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.